Literature DB >> 10860094

Erectile dysfunction, sildenafil and cardiovascular risk.

K K Chew1, B G Stuckey, P L Thompson.   

Abstract

Cardiovascular risk factors are commonly associated with erectile dysfunction and should be identified and treated. Patients with cardiovascular diseases should be assessed and counselled regarding their fitness for sexual activity. The danger of concurrent use of sildenafil and nitrates under any circumstances, regardless of age and sex, must be highlighted at all levels of the community. Sildenafil is absolutely contraindicated in patients receiving treatment with long-acting nitrates for ischaemic heart disease. Patients who need sublingual short-acting nitrates infrequently should not be precluded from taking sildenafil, provided they are aware that sildenafil is not to be taken within 24 h of taking the nitrate.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10860094

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  2 in total

Review 1.  Erectile dysfunction in patients with cardiovascular disease.

Authors:  A J M Oude Ophuis; A A B Lycklama À Nijeholt
Journal:  Neth Heart J       Date:  2006-04       Impact factor: 2.380

Review 2.  Erectile dysfunction and the cardiovascular patient: endothelial dysfunction is the common denominator.

Authors:  H Solomon; J W Man; G Jackson
Journal:  Heart       Date:  2003-03       Impact factor: 5.994

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.